Autopsy report · NCT02527772

Liposomal Doxorubicin Plus Gemcitabine Versus Oxaliplatin Plus Fluorouracil/Leucovorin for Hepatocellular Carcinoma

Cause of deathOther Automatic label, confidence 0.3, unverified. How labels are made.

“It doesn't meet the requirements of randomized trials”

The sponsor’s own words in the registry.

Life of this trial

Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status: Withdrawn
Phase: Phase 2, Phase 3
Sponsor: Guangxi Medical University
Sponsor type: University, hospital or other
Conditions: Hepatocellular Carcinoma
Interventions: Liposomal Doxorubicin+Gemcitabine; FOLFOX4
Participants: 0

Look deeper

The official registry record (the source of truth)
Record history: every change the sponsor made
Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.